Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
- PMID: 36306792
- PMCID: PMC9669212
- DOI: 10.1016/j.ccell.2022.10.001
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
Abstract
Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy necessitates optimization and maintenance of activated effector T cells (Teff). We prospectively collected and applied multi-omic analyses to paired pre- and post-treatment PDAC specimens collected in a platform neoadjuvant study of granulocyte-macrophage colony-stimulating factor-secreting allogeneic PDAC vaccine (GVAX) vaccine ± nivolumab (anti-programmed cell death protein 1 [PD-1]) to uncover sensitivity and resistance mechanisms. We show that GVAX-induced tertiary lymphoid aggregates become immune-regulatory sites in response to GVAX + nivolumab. Higher densities of tumor-associated neutrophils (TANs) following GVAX + nivolumab portend poorer overall survival (OS). Increased T cells expressing CD137 associated with cytotoxic Teff signatures and correlated with increased OS. Bulk and single-cell RNA sequencing found that nivolumab alters CD4+ T cell chemotaxis signaling in association with CD11b+ neutrophil degranulation, and CD8+ T cell expression of CD137 was required for optimal T cell activation. These findings provide insights into PD-1-regulated immune pathways in PDAC that should inform more effective therapeutic combinations that include TAN regulators and T cell activators.
Keywords: CD137; IL-8; RNA sequencing; Th17; anti-PD-1 antibody; immune checkpoint inhibitor; multiplex immunohistochemistry; pancreatic cancer; tumor-associated neutrophils; vaccine therapy.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.Z. receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, iTeos, Amgen, NovaRock, Inxmed, Halozyme, and Abmeta. L.Z. is a paid consultant/Advisory Board member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Natera, Novagenesis, Snow Lake Capitals, BioArdis, Tempus, Amberstone, Pfizer, Tavotek, and Mingruizhiyao. L.Z. holds shares at Alphamab, Amberstone, and Mingruizhiyao. E.J.F. is on the scientific advisory board of Resistance Bio and is a paid consultant for Merck and Mestag Therapeutics. E.J. receives grant support from Lustgarten Foundation, Bristol-Meyer Squibb, Genentech, and AstroZeneca; is a paid consultant for NextCure, Genocea, DragonFly, Stimit, CSTONE, Achilles, and Candel; is on the advisory board of Parker Institute and Break Through Cancer; is a founder of Abmeta Biotech; and is the Chief Medical Advisor for the Lustgarten Foundation.
Figures
Similar articles
-
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer.J Immunother Cancer. 2018 Nov 13;6(1):118. doi: 10.1186/s40425-018-0435-6. J Immunother Cancer. 2018. PMID: 30424804 Free PMC article.
-
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.Cancer Lett. 2021 Feb 28;499:99-108. doi: 10.1016/j.canlet.2020.11.041. Epub 2020 Nov 30. Cancer Lett. 2021. PMID: 33271264 Free PMC article.
-
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.Nat Commun. 2023 Jun 20;14(1):3650. doi: 10.1038/s41467-023-39196-9. Nat Commun. 2023. PMID: 37339979 Free PMC article.
-
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.Front Immunol. 2018 Aug 15;9:1878. doi: 10.3389/fimmu.2018.01878. eCollection 2018. Front Immunol. 2018. PMID: 30158932 Free PMC article. Review.
-
Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.Adv Cancer Res. 2023;159:113-143. doi: 10.1016/bs.acr.2023.02.003. Epub 2023 Mar 10. Adv Cancer Res. 2023. PMID: 37268394 Review.
Cited by
-
Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology.Brief Bioinform. 2024 Jul 25;25(5):bbae421. doi: 10.1093/bib/bbae421. Brief Bioinform. 2024. PMID: 39179248 Free PMC article. Review.
-
The Latest Look at PDT and Immune Checkpoints.Curr Issues Mol Biol. 2024 Jul 8;46(7):7239-7257. doi: 10.3390/cimb46070430. Curr Issues Mol Biol. 2024. PMID: 39057071 Free PMC article. Review.
-
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5. Nat Commun. 2024. PMID: 39013886 Free PMC article. Clinical Trial.
-
Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers.Cell Rep Med. 2024 Jul 16;5(7):101648. doi: 10.1016/j.xcrm.2024.101648. Epub 2024 Jul 9. Cell Rep Med. 2024. PMID: 38986624 Free PMC article.
-
Machine learning for the identification of neoantigen-reactive CD8 + T cells in gastrointestinal cancer using single-cell sequencing.Br J Cancer. 2024 Jul;131(2):387-402. doi: 10.1038/s41416-024-02737-0. Epub 2024 Jun 7. Br J Cancer. 2024. PMID: 38849478
References
-
- Avram G, Sánchez-Sendra B, Martín JM, Terrádez L, Ramos D, and Monteagudo C (2013). The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology 63, 852–861. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials